Does UPMC Health Plan Cover Forteo (Teriparatide)?

What Is Forteo and Why Is It Prescribed?

Forteo (teriparatide) is a recombinant parathyroid hormone analog manufactured by Eli Lilly and Company. Administered as a once-daily 20 mcg subcutaneous injection, it works by stimulating new bone formation rather than simply slowing bone loss. This anabolic mechanism sets it apart from antiresorptive agents like alendronate or denosumab.

The FDA first approved teriparatide in 2002 for postmenopausal women at high fracture risk, and the label was later expanded to include men with primary or hypogonadal osteoporosis and both men and women with glucocorticoid-induced osteoporosis [1]. In the key Fracture Prevention Trial (N=1,637), teriparatide 20 mcg/day reduced new vertebral fractures by 65% relative to placebo over a median 19-month treatment period (RR 0.35 to 95% CI 0.22-0.55, P<0.001) and reduced non-vertebral fragility fractures by 53% [2].

Because Forteo is expensive (list price exceeding $3,000/month at many pharmacies), insurance coverage decisions carry enormous weight for patients. UPMC Health Plan, which covers more than 4 million members across Pennsylvania and surrounding states, follows formulary and utilization-management policies that determine whether a member pays a modest copay or faces a five-figure annual bill.

How UPMC Health Plan Formularies Are Structured

UPMC Health Plan operates multiple distinct plan types: commercial employer-sponsored plans, individual Marketplace plans, Medicaid managed care (UPMC for You), Medicare Advantage (UPMC for Life), and CHIP plans. Each plan maintains its own Evidence of Coverage and its own formulary drug list, so Forteo coverage terms vary by the specific contract.

On commercial plans and Medicare Advantage plans, specialty medications like Forteo are placed on Tier 4 or Tier 5. These tiers carry the highest member cost-share, often expressed as a percentage of the drug's allowed cost (coinsurance) rather than a flat dollar copay. A 30-day supply on a 20% coinsurance tier with a $3,200 negotiated price means $640 out of pocket before any manufacturer assistance.

UPMC publishes formulary documents annually. The UPMC Health Plan drug formulary search tool at upmc.com/healthplan allows members to enter their plan ID and search "teriparatide" to see the exact tier, any coverage restrictions, and whether step therapy applies for their specific contract. Checking this directly is the most reliable first step because formulary tier assignments change each plan year. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines note that access barriers to anabolic agents remain "a major obstacle to guideline-concordant osteoporosis care" [3].

Prior Authorization Requirements for Forteo at UPMC

Prior authorization (PA) is not optional. Every UPMC plan type that covers Forteo requires a PA request before the prescription will be paid. The prescribing clinician, not the patient, submits this documentation, typically through UPMC's provider portal or via fax.

Standard PA criteria across most UPMC plan types require all of the following:

Diagnosis documentation. A confirmed diagnosis of osteoporosis by DXA scan showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip. Some PA forms accept a T-score below -2.0 when accompanied by a documented low-trauma (fragility) fracture of the hip, vertebra, or wrist within the prior 24 months.

Step therapy completion. The member must have tried and either failed to respond to or have a documented contraindication to at least one oral bisphosphonate. Alendronate (Fosamax, generic) is the usual first-line agent required. "Failed" therapy is typically defined as a new low-trauma fracture after at least 12 months of consistent bisphosphonate use, or a continued decline in BMD of greater than 5% at any measured site over 12 months on therapy.

Lab values and safety checks. A baseline serum calcium, 25-hydroxyvitamin D, and renal function panel are generally required. Teriparatide is contraindicated in patients with hypercalcemia, Paget's disease, prior radiation to the skeleton, or unexplained alkaline phosphatase elevation, all of which the PA form addresses.

Prescriber specialty. Some UPMC PA policies restrict Forteo approval to prescriptions originating from endocrinologists, rheumatologists, or orthopedic surgeons, though primary care physicians may also qualify in many instances. Confirming this with UPMC's provider relations line before submitting avoids unnecessary delays.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) guidelines state that pharmacological treatment is recommended for postmenopausal women and men age 50 and older who have a hip or vertebral fracture, a DXA T-score <-2.5 at any site, or a 10-year probability of major osteoporotic fracture of 20% or higher on the FRAX tool [4]. Documenting FRAX scores in the PA submission can strengthen the clinical narrative even when T-score thresholds alone are borderline.

Step-by-Step PA Submission Guide for Forteo at UPMC

Submitting a complete, well-documented PA package on the first attempt dramatically reduces the 72-hour standard review timeline to a clean approval rather than a pend-for-additional-information letter.

Step 1. Verify eligibility and formulary status. The prescriber's office calls UPMC provider services at 1-888-876-2756 (commercial) or 1-800-440-4026 (Medicare) to confirm the patient's active coverage, current Forteo formulary status, and the exact PA criteria for that plan year.

Step 2. Gather clinical documentation. Pull together the most recent DXA report (within 24 months), fracture imaging or radiology reports if applicable, a 6-12 month bisphosphonate dispensing history from the pharmacy benefits manager, and any relevant labs (calcium, 25-OH vitamin D, creatinine, alkaline phosphatase).

Step 3. Calculate FRAX score. The WHO FRAX tool at sheffield.ac.uk/FRAX provides a 10-year probability of major osteoporotic fracture and hip fracture. Including a FRAX major fracture probability at or above 20% substantiates high fracture risk even if a single T-score value is borderline.

Step 4. Submit PA through the provider portal. UPMC Health Plan accepts electronic PA submissions through NaviNet and via eviCore (the specialty pharmacy benefit management partner for many UPMC plans). Attach all supporting documents in a single PDF to avoid piecemeal processing.

Step 5. Track and follow up. Standard PA decisions are due within 72 hours for non-urgent requests and 24 hours for urgent requests under Pennsylvania Insurance Department regulations. If the decision is not received within that window, call provider services and request the case number.

What Happens If UPMC Denies Forteo Coverage?

A denial is not necessarily final. Pennsylvania law and federal Marketplace plan rules provide structured appeal rights that clinicians and patients should use aggressively when the clinical case is strong.

Internal appeal. File a formal written appeal within 60 days of the denial notice. The appeal must include a letter of medical necessity from the prescriber, ideally signed by the treating specialist, explaining why teriparatide is medically necessary and why alternative therapies are inadequate. Cite the specific clinical criteria from the denial letter and counter each one with documentation.

Peer-to-peer review. Before the formal internal appeal, request a peer-to-peer call between the prescribing clinician and UPMC's reviewing physician. This call resolves many denials within 24-48 hours without going through the full appeal process. Schedulers often have same-day or next-day availability.

External Independent Medical Review (IMR). If the internal appeal fails, Pennsylvania law provides the right to an external IMR by an independent organization not affiliated with UPMC. Submit the IMR request to the Pennsylvania Insurance Department within 15 months of the original denial. For Medicare Advantage members, the Qualified Independent Contractor (QIC) level provides equivalent protection under CMS regulations.

The American College of Rheumatology notes in its 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis that teriparatide holds a "strong recommendation" for patients on long-term glucocorticoid therapy (>7.5 mg/day prednisone equivalent for more than 3 months) who have a moderate-to-high fracture risk [5]. This guideline language is powerful evidence in an appeal for patients in this specific subgroup.

Cost and Manufacturer Assistance Programs

Even with UPMC coverage, specialty tier cost-share can make Forteo prohibitive. Several programs can reduce or eliminate that gap.

Eli Lilly Cares Foundation Patient Assistance Program. Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for Forteo at no cost through the Lilly Cares Foundation. Applications are available at lillycares.com.

Lilly Forteo Copay Card. For commercially insured patients (not Medicare or Medicaid), the Lilly copay assistance card reduces the member's monthly cost-share to as low as $25/month. This card works at most retail and specialty pharmacies that process manufacturer copay offset cards. Medicare Part D members are not eligible due to federal anti-kickback statute restrictions on manufacturer copay assistance in government programs.

Medicare Extra Help (Low Income Subsidy). Medicare Part D members with limited income and resources may qualify for the federal Extra Help program, which reduces specialty tier cost-share to roughly $4-$10 per month for covered drugs. Applications go through the Social Security Administration at ssa.gov/extrahelp.

State Pharmaceutical Assistance Programs. Pennsylvania's PACE and PACENET programs provide prescription cost assistance to residents age 65 and older who meet income requirements. PACE covers patients with income at or below $14,500 (single) or $17,700 (married) annually; PACENET extends to $23,500 (single) or $31,500 (married) [6].

GoodRx and cash-pay alternatives. The teriparatide biosimilar Bonsity (Radius Health) launched in 2022 with a list price approximately 80% lower than branded Forteo, and UPMC formularies in 2024 began placing Bonsity on preferred specialty tiers in many plans. Asking the prescriber to write "teriparatide" generically or specifically "Bonsity" may result in a lower-tier PA approval and meaningfully lower cost-share.

Covered Alternatives to Forteo at UPMC

When Forteo PA is denied or while a step-therapy requirement is being fulfilled, other osteoporosis medications on UPMC formularies may be covered with less friction.

Oral bisphosphonates (Tier 1-2 generics). Alendronate 70 mg weekly and risedronate 35 mg weekly are first-line generics on virtually every UPMC formulary. In the Fracture Intervention Trial (FIT, N=2,027), alendronate reduced vertebral fracture risk by 47% at 3 years in women with prior vertebral fractures [7]. These drugs cost as little as $4-$8/month at most pharmacies.

IV zoledronic acid (Reclast). An annual intravenous infusion, zoledronic acid 5 mg reduced hip fracture by 41% and vertebral fracture by 70% in HORIZON-PFT (N=7,765) over 3 years [8]. UPMC generally covers this with a prior authorization for patients unable to tolerate oral bisphosphonates due to esophageal disease or adherence issues.

Denosumab (Prolia). A subcutaneous injection given every 6 months, denosumab reduces vertebral fracture risk by 68% and hip fracture by 40% over 36 months per the FREEDOM trial (N=7,808) [9]. UPMC Health Plan covers Prolia on most commercial formularies with PA for patients with T-scores <-2.5 and bisphosphonate intolerance or refractoriness.

Romosozumab (Evenity). Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive properties, is a Tier 5 specialty drug at UPMC. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced vertebral fracture by 48% and hip fracture by 38% versus alendronate alone over 24 months [10]. PA criteria are similar to Forteo. Romosozumab carries an FDA boxed warning for increased cardiovascular risk in patients with a history of myocardial infarction or stroke, which UPMC PA reviewers weigh in their decisions.

Abaloparatide (Tymlos). Another PTH analog, abaloparatide 80 mcg/day subcutaneous injection, showed 86% reduction in vertebral fracture and 43% reduction in nonvertebral fracture versus placebo in ACTIVE (N=2,463) at 18 months [11]. UPMC formulary placement and PA criteria for Tymlos are nearly identical to those for Forteo. For patients denied Forteo, requesting Tymlos under the same clinical documentation may succeed on a different step-therapy pathway.

Special Populations: Medicare Advantage vs. Commercial UPMC Plans

Coverage mechanics differ in one important way depending on whether a patient is on a UPMC commercial plan or UPMC for Life (Medicare Advantage).

Commercial plans. Specialty pharmacy benefits for Forteo typically flow through UPMC's pharmacy benefit manager. Members fill prescriptions through a specialty pharmacy network (often CuraScript or Accredo). The annual deductible and out-of-pocket maximum reset each January 1, which matters enormously for expensive specialty drugs. Starting a Forteo fill in January means the out-of-pocket maximum is hit earlier in the year, reducing the effective cost for the remainder.

UPMC for Life (Medicare Advantage). Medicare Advantage plans with Part D drug benefits use the standard CMS-defined tier structure. Forteo falls under the specialty tier with cost-shares typically ranging from 25% to 33% coinsurance. The Medicare Part D catastrophic coverage threshold in 2025 is $8 to 000 in true out-of-pocket spending, after which covered drugs cost $0 for the remainder of the benefit year for most members. Patients who hit this threshold by mid-year effectively receive the remaining months of Forteo at no cost.

UPMC for You (Medicaid). Pennsylvania Medicaid managed care covers teriparatide under the state's fee-for-service preferred drug list (PDL). UPMC for You follows the state PDL. As of the most recent Pennsylvania PDL, teriparatide requires PA with criteria similar to commercial plans. However, member cost-share for Medicaid-enrolled patients is nominal (typically $1-$3 per prescription), making affordability less of a barrier once PA is approved.

How Long Does UPMC Approve Forteo Coverage?

UPMC PA approvals for Forteo are almost universally time-limited. Initial approvals generally cover 6 to 12 months. A renewal PA is then required, and renewal criteria typically ask for evidence that treatment is ongoing, that a new DXA has been performed (or is scheduled), and that no safety concerns such as hypercalcemia or symptomatic orthostatic hypotension have emerged.

The FDA limits teriparatide use to a cumulative lifetime maximum of 24 months, a restriction rooted in findings from a long-term rat carcinogenicity study showing dose-dependent osteosarcoma, though no causal link to human osteosarcoma has been established in post-market surveillance covering more than 20 years of clinical use [1]. UPMC PA policies mirror this FDA-mandated 24-month lifetime cap. Once a patient has exhausted 24 months of teriparatide, coverage will not be extended, regardless of clinical circumstances, and the treating clinician should plan a sequential antiresorptive agent (typically denosumab or zoledronic acid) to preserve bone gains made during anabolic therapy.

Documentation Checklist for Prescribers

Getting PA right the first time saves weeks of delay and preserves patient access during a period when fracture risk is elevated. The following documentation package gives the strongest possible submission.

A DXA report within 24 months with T-scores at lumbar spine, femoral neck, and total hip. Radiology or ED reports for any fragility fractures occurring since the original osteoporosis diagnosis. A pharmacy dispensing record or refill history confirming at least 6-12 months of oral bisphosphonate use. A FRAX calculation printout with the patient's specific 10-year probability figures. A letter of medical necessity from the prescriber explaining the specific reason standard antiresorptive therapy is inadequate, whether that is documented BMD decline on therapy, a fracture while adherent to bisphosphonate, or a contraindication such as Barrett's esophagus or chronic kidney disease stage 3B-5 precluding bisphosphonate use. Baseline labs: serum calcium, 25-hydroxyvitamin D, serum creatinine, and alkaline phosphatase. Confirmation that the patient does not have a personal history of bone malignancy, skeletal radiation, or Paget's disease.

A complete package submitted once is far more effective than a thin submission followed by multiple rounds of pend letters and additional information requests. UPMC's internal review turnaround clock does not start until the file is deemed complete, so gaps in documentation directly delay a patient's access to treatment.

The Bone Health and Osteoporosis Foundation clinical practice guide states: "Treatment should be initiated promptly in patients at very high or imminent fracture risk, and delays in access to anabolic therapy translate directly into preventable fractures." [4] Including this language verbatim in the medical necessity letter reinforces the urgency of the request.